Clinical Evaluation, Prescription Review and Medicines Optimisation

Scope and time budget

Questions here are practical. A medication list, a result or a scenario is presented, and you decide what is safe, what needs monitoring and what to say. About one in five items involves a child, and renal impairment, pregnancy and interactions recur.

What is tested

• Prescription review. Appropriateness, dose, duplication, contraindications and omissions on a medicines list.
• Reconciliation. Comparing lists across care transitions and resolving differences.
• Polypharmacy and deprescribing. Identifying medicines with doubtful benefit in older people.
• Interactions. Drug-drug and drug-food, including enzyme inducers and inhibitors, QT prolongation and serotonergic combinations.
• Adverse reactions. Recognition, management and Yellow Card reporting.
• Special populations. Renal and hepatic impairment, pregnancy, breastfeeding and children.
• High-risk drugs. Methotrexate, opioids, insulin, anticoagulants, valproate and narrow therapeutic index medicines.
• Monitoring. Therapeutic drug monitoring and laboratory results, such as sodium, potassium, creatinine and INR.
• Tests. Blood pressure, ECG features, peak flow and HbA1c.
• Evidence. Appraising trials, NICE evidence levels and measures such as number needed to treat.
• Communication. Shared decision-making, adherence support and counselling on devices such as inhalers, injectables and patches.
• Minor ailments. OTC recommendation with red-flag symptoms and referral.
• Emergencies. Medical emergencies and first aid in pharmacy.
• Safety. Medication incidents, error prevention and unlicensed or off-label use.

UK guideline anchors

• BNF and BNFc. Doses, cautions, renal and hepatic advice and interactions, with child doses by age or weight.
• NICE and CKS. Treatment pathways, monitoring intervals and evidence levels.
• MHRA. Drug Safety Update notices and the Yellow Card scheme.
• Units. HbA1c is in mmol/mol, eGFR in mL/min/1.73 m2, creatinine in micromol/L and glucose in mmol/L.
• Weekly methotrexate. A medicine taken once a week for conditions such as rheumatoid arthritis and psoriasis, so a daily prescription is a safety error. Confirm details in the BNF.

A method for reviewing a medicines list

1. Know the patient. Age, weight, kidney and liver function, pregnancy status, allergies and what the question asks.
2. Check each medicine for a reason. Is there an indication? Is anything duplicated? Is anything missing for a condition on the list?
3. Check dose and form. Does the dose fit the patient? Is a once-weekly medicine written as daily?
4. Check interactions. Look for enzyme inducers and inhibitors, additive bleeding, QT prolongation, serotonergic combinations and potassium.
5. Check monitoring. Is a test due? Does a recent result change the plan?
6. Choose the action. Supply, supply with advice, contact the prescriber or refer. Record what you did.

Practise this on short lists until it takes under a minute. The skill transfers to every therapeutic domain, which is why this domain carries more weight than its label suggests.

Evidence appraisal in brief

The framework lists critical evaluation of evidence among its high-weighted outcomes. Expect questions that give a small trial summary or a table and ask what it shows. Know the language of absolute and relative risk reduction, number needed to treat as the reciprocal of the absolute risk reduction, confidence intervals and whether they cross the line of no effect, and the differences between randomised trials, cohort studies and case-control studies. Learn how bias and confounding affect a result, and what the NICE levels of evidence say about confidence in a recommendation.

OTC requests and red flags

Minor-ailment questions test whether you recognise when not to sell. Learn, for common requests such as cough, headache, diarrhoea, indigestion and skin complaints, the symptoms that mean referral: age extremes, pregnancy, persistent or worsening symptoms, weight loss, blood, severe pain, and signs of serious infection or sepsis. The best answer usually asks about those features before recommending anything, and refers when they are present.

Medicines reconciliation and transitions of care

Discrepancies cluster at admission, transfer and discharge. A medicine is omitted, duplicated, changed in dose or continued after it should have stopped. Reconciliation questions give two lists, for example a GP record and a discharge summary, and ask which difference matters most or what to do first. Prioritise the differences that could cause harm quickly: anticoagulants, insulin, opioids, medicines with a narrow therapeutic index and anything stopped for a reason that has not been recorded. Then confirm with the prescriber, update the record and inform the patient.

Three typical traps

1. The interaction you did not look for. The question is about a new medicine, and the trap is an existing one on the list. Read the whole list first.
2. The wrong population. Renal function, age or pregnancy changes the answer. Check these in the stem before you choose.
3. The over-treatment answer. Sometimes the best response is to stop, refer or ask the prescriber, not to supply. Choose the safest action within the pharmacist's role.

How to revise it

1. Practise with lists. Take a ten-item medicines list and look for duplication, interactions, dose and omissions.
2. Learn monitoring. For each high-risk drug, write what is monitored, when and what you do if the result is abnormal.
3. Revise evidence terms. Absolute and relative risk, number needed to treat, confidence intervals and types of study.
4. Rehearse red flags. For common OTC requests, list the symptoms that mean refer.
5. Use the error log. Tag errors as list-reading, population or role, and fix the commonest.

Next, read high-yield topics for the high-risk drug groups, and the law domain for supply rules. Back to the hub.